Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review

Table 5 The CLOT and CATCH studies[80,81]: Study-population characteristics and study outcomes

	CLOT	CATCH	VKA	Dalteparin	P	VKA	Tinzaparin	P
Study-population characteristics
n	676	900
Women	52%	59%
Median age (yr)	63	59
ECOG 0-1	63%	77%
Metastasized cancer	67%	55%
Brest cancer	17.6%	9%
Colo-rectal cancer	17.8%	13%
Lung cancer	14.8%	12%
Gynecological cancer	11.2%	23%
Pancreatic cancer	4.8%
Urogenital cancers	14.2%
Brain cancers	5.5%
Hematological cancers	10%	10%
Study outcomes
VTE			15.8%	8.0%	0.002	10.0%	6.9%	0.07
DVT			11.0%	4.2%		5.3	2.7	0.04
Fatal PE			2.1%	1.7%		3.8%	3.8%
Non-fatel PE			2.7%	2.7%		0.7%	0.4%
Major bleeding			4%	6%	0.25	2.7%	2.9%
CRNM-bleeding						16%	11%	0.03
Any bleeding			19%	14%	0.09
6-mo mortality			41%	39%		41%	40%
INR < 2			30%			26%
INR 2-3			46%			47%

VKA: Vitamin K antagonist; VTE: Venous thromboembolic event; DVT: Deep vein thrombosis; PE: Pulmonary embolism; INR: International normalized ratios.